Last week, the results of ORBITA were published. This clinical trial tested #coronary angioplasty and #stenting versus optimal medical management in patients with single-vessel coronary artery disease. It was a resoundingly negative trial, meaning that adding stenting to drug management didn?t result in detectable clinical improvement. What was distinctive about this trial is that it used a sham #procedure (i.e., placebo) control, which few trials testing surgery or a procedure use. The results of ORBITA emphasize how important sham procedure controls are, whenever they can be ethically used, read more...

11 View, 0 Like, 0 dislike, 3 months ago

InspireMD, Inc. , a leader in embolic prevention systems / thrombus management technologies and neurovascular devices, today announced the #publication of an #independent observational study conducted by Tomoyuki Umemoto, MD and colleagues in the December 2017 issue of the journal EuroIntervention demonstrating the advantage of CGuarda EPS in reducing stent plaque prolapse in carotid #artery stenting patients. The aim of this study was to compare plaque prolapse after carotid artery stenting with CGuarda versus a competing device as assessed by optical coherence tomography , a technique that read more...

27 View, 0 Like, 0 dislike, 1 month ago

Most Popular

Recent popular